中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 40 Issue 6
Jun.  2024
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(6): 1255-1258

Research advances in drug-induced autoimmune-like hepatitis

DOI: 10.12449/JCH240628
  • 1.

    Department of Gastroenterology，The Second Affiliated Hospital of Kunming Medical University，Kunming 650000，China

  • 2.

    Department of Gastroenterology，Yan’an Hospital Affiliated to Kunming Medical University，Kunming 650051，China

Research funding:

National Natural Science Foundation of China (82160106)

More Information
  • Corresponding author: XU Zhiyuan， xuzhiyuan0109@163.com （ORCID： 0000-0003-0289-5947）
  • Received Date: 2023-10-14
  • Accepted Date: 2023-10-30
  • Published Date: 2024-06-25
    Abstract
  • Drug-induced autoimmune-like hepatitis （DI-ALH） is a special clinical phenotype of drug-induced liver injury and has similar clinical features and laboratory test results to autoimmune hepatitis， and it is often difficult to distinguish them through liver biopsy. Therefore， correct differential diagnosis DI-ALH and autoimmune hepatitis is a crucial and difficult point in clinical practice. This article analyzes the research advances in the pathogenesis， clinical features， diagnosis and treatment， and prognosis of DI-ALH， in order to provide ideas for the diagnosis and treatment of such diseases among clinicians.

     

    • FullText(HTML)
    • References(35)
  • [1]
    Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug-Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese guideline for diagnosis and management of drug-induced liver injury(2023 version)[J]. Chin J Gastroenterol, 2022, 27( 6): 341- 375. DOI: 10.3760/cma.j.cn501113-20230419-00176-1.

    中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 胃肠病学, 2022, 27( 6): 341- 375. DOI: 10.3760/cma.j.cn501113-20230419-00176-1.
    [2]
    HOOFNAGLE JH, BJÖRNSSON ES. Drug-induced liver injury-Types and phenotypes[J]. N Engl J Med, 2019, 381( 3): 264- 273. DOI: 10.1056/nejmra1816149.
    [3]
    QIN TT, MUHAMMAD H, ZHOU Y, et al. Macrophage malfunction in Triptolide-induced indirect hepatotoxicity[J]. Front Pharmacol, 2022, 13: 981996. DOI: 10.3389/fphar.2022.981996.
    [4]
    BRUNO CD, FREMD B, CHURCH RJ, et al. HLA associations with infliximab-induced liver injury[J]. Pharmacogenomics J, 2020, 20( 5): 681- 686. DOI: 10.1038/s41397-020-0159-0.
    [5]
    GUO CQ, LIU WJ, LIU Z, et al. Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury[J]. Hepatology, 2023, 78( 1): 45- 57. DOI: 10.1097/HEP.0000000000000044.
    [6]
    ANDRADE RJ, AITHAL GP, de BOER YS, et al. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis(DI-ALH): An expert opinion meeting report[J]. J Hepatol, 2023, 79( 3): 853- 866. DOI: 10.1016/j.jhep.2023.04.033.
    [7]
    BESSONE F, FERRARI A, HERNANDEZ N, et al. Nitrofurantoin-induced liver injury: Long-term follow-up in two prospective DILI registries[J]. Arch Toxicol, 2023, 97( 2): 593- 602. DOI: 10.1007/s00204-022-03419-7.
    [8]
    de BOER YS, KOSINSKI AS, URBAN TJ, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury[J]. Clin Gastroenterol Hepatol, 2017, 15( 1): 103- 112. e 2. DOI: 10.1016/j.cgh.2016.05.043.
    [9]
    BJÖRNSSON ES, MEDINA-CALIZ I, ANDRADE RJ, et al. Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports[J]. Hepatol Commun, 2022, 6( 8): 1895- 1909. DOI: 10.1002/hep4.1959.
    [10]
    MIKIEWICZ M, OTROCKA-DOMAGAŁA I, PAŹDZIOR-CZAPULA K. Influence of simvastatin on hepatocytes-histopathological and immunohistochemical study[J]. Pol J Vet Sci, 2019, 22( 2): 263- 270. DOI: 10.24425/pjvs.2019.127095.
    [11]
    SHAO YM, ZHANG Y, YIN X, et al. Herb-induced autoimmune-like hepatitis associated with Xiang-Tian-Guo(Swietenia macrophylla seeds): A case report and literature review[J]. Medicine, 2021, 100( 2): e24045. DOI: 10.1097/MD.0000000000024045.
    [12]
    BRIL F, DIFFALHA S AL, DEAN M, et al. Autoimmune hepatitis developing after coronavirus disease 2019(COVID-19) vaccine: Causality or casualty?[J]. J Hepatol, 2021, 75( 1): 222- 224. DOI: 10.1016/j.jhep.2021.04.003.
    [13]
    EFE C, KULKARNI AV, TERZIROLI BERETTA-PICCOLI B, et al. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome[J]. Hepatology, 2022, 76( 6): 1576- 1586. DOI: 10.1002/hep.32572.
    [14]
    MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases[J]. Hepatology, 2020, 72( 2): 671- 722. DOI: 10.1002/hep.31065.
    [15]
    BJÖRNSSON E, TALWALKAR J, TREEPRASERTSUK S, et al. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis[J]. Hepatology, 2010, 51( 6): 2040- 2048. DOI: 10.1002/hep.23588.
    [16]
    STEPHENS C, ROBLES-DIAZ M, MEDINA-CALIZ I, et al. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry[J]. J Hepatol, 2021, 75( 1): 86- 97. DOI: 10.1016/j.jhep.2021.01.029.
    [17]
    GARCÍA-CORTÉS M, ORTEGA-ALONSO A, MATILLA-CABELLO G, et al. Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries[J]. Liver Int, 2023, 43( 8): 1749- 1760. DOI: 10.1111/liv.15623.
    [18]
    SUN Y, ZENG Z, YANG L, et al. Clinical characteristics of drug-induced liver injury combined with autoimmune disease[J/CD]. Chin J Liver Dis(Electronic Version), 2023, 15( 4): 28- 32. DOI: 10.3969/j.issn.1674-7380.2023.04.006.

    孙月, 曾湛, 杨柳, 等. 药物性肝损伤合并自身免疫病患者的临床特点[J/CD]. 中国肝脏病杂志(电子版), 2023, 15( 4): 28- 32. DOI: 10.3969/j.issn.1674-7380.2023.04.006.
    [19]
    WEBER S, BENESIC A, BUCHHOLTZ ML, et al. Antimitochondrial rather than antinuclear antibodies correlate with severe drug-induced liver injury[J]. Dig Dis, 2021, 39( 3): 275- 282. DOI: 10.1159/000511635.
    [20]
    SUZUKI A, BRUNT EM, KLEINER DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury[J]. Hepatology, 2011, 54( 3): 931- 939. DOI: 10.1002/hep.24481.
    [21]
    FEBRES-ALDANA CA, ALGHAMDI S, KRISHNAMURTHY K, et al. Liver fibrosis helps to distinguish autoimmune hepatitis from DILI with autoimmune features: A review of twenty cases[J]. J Clin Transl Hepatol, 2019, 7( 1): 21- 26. DOI: 10.14218/JCTH.2018.00053.
    [22]
    LAMMERT C, ZHU CS, LIAN Y, et al. Exploratory study of autoantibody profiling in drug-induced liver injury with an autoimmune phenotype[J]. Hepatol Commun, 2020, 4( 11): 1651- 1663. DOI: 10.1002/hep4.1582.
    [23]
    TAUBERT R, ENGEL B, DIESTELHORST J, et al. Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis[J]. Hepatology, 2022, 75( 1): 13- 27. DOI: 10.1002/hep.32134.
    [24]
    TESCHKE R, DANAN G. Advances in idiosyncratic drug-induced liver injury issues: New clinical and mechanistic analysis due to roussel uclaf causality assessment method use[J]. Int J Mol Sci, 2023, 24( 13): 10855. DOI: 10.3390/ijms241310855.
    [25]
    WEBER S, GERBES AL. Relapse and need for extended immunosuppression: Novel features of drug-induced autoimmune hepatitis[J]. Digestion, 2023, 104( 3): 243- 248. DOI: 10.1159/000528329.
    [26]
    European Association for the Study of the Liver. EASL clinical practice guidelines: Drug-induced liver injury[J]. J Hepatol, 2019, 70( 6): 1222- 1261. DOI: 10.1016/j.jhep.2019.02.014.
    [27]
    BJÖRNSSON HK, GUDBJORNSSON B, BJÖRNSSON ES. Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment[J]. J Hepatol, 2022, 76( 1): 86- 92. DOI: 10.1016/j.jhep.2021.08.024.
    [28]
    KUZU UB, ÖZTAŞ E, TURHAN N, et al. Clinical and histological features of idiosyncratic liver injury: Dilemma in diagnosis of autoimmune hepatitis[J]. Hepatol Res, 2016, 46( 4): 277- 291. DOI: 10.1111/hepr.12530.
    [29]
    MARTÍNEZ-CASAS OY, DÍAZ-RAMÍREZ GS, MARÍN-ZULUAGA JI, et al. Differential characteristics in drug-induced autoimmune hepatitis[J]. JGH Open, 2018, 2( 3): 97- 104. DOI: 10.1002/jgh3.12054.
    [30]
    BJÖRNSSON ES, BERGMANN O, JONASSON JG, et al. Drug-induced autoimmune hepatitis: Response to corticosteroids and lack of relapse after cessation of steroids[J]. Clin Gastroenterol Hepatol, 2017, 15( 10): 1635- 1636. DOI: 10.1016/j.cgh.2017.05.027.
    [31]
    UENO M, TAKABATAKE H, KAYAHARA T, et al. Long-term outcomes of drug-induced autoimmune-like hepatitis after pulse steroid therapy[J]. Hepatol Res, 2023, 53( 11): 1073- 1083. DOI: 10.1111/hepr.13940.
    [32]
    LUCENA MI, KAPLOWITZ N, HALLAL H, et al. Recurrent drug-induced liver injury(DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis[J]. J Hepatol, 2011, 55( 4): 820- 827. DOI: 10.1016/j.jhep.2010.12.041.
    [33]
    ROBLES-DIAZ M, LUCENA MI, KAPLOWITZ N, et al. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury[J]. Gastroenterology, 2014, 147( 1): 109- 118. e 5. DOI: 10.1053/j.gastro.2014.03.050.
    [34]
    LO RE V 3, HAYNES K, FORDE KA, et al. Risk of acute liver failure in patients with drug-induced liver injury: Evaluation of hy’s law and a new prognostic model[J]. Clin Gastroenterol Hepatol, 2015, 13( 13): 2360- 2368. DOI: 10.1016/j.cgh.2015.06.020.
    [35]
    DEVARBHAVI H, ASRANI SK, ARAB JP, et al. Global burden of liver disease: 2023 update[J]. J Hepatol, 2023, 79( 2): 516- 537. DOI: 10.1016/j.jhep.2023.03.017.
    • Relative Articles

  • Relative Articles

    [1]Dan LIU, Tiantian YAO, Yuhan ZHANG, Guiqiang WANG, Yan WANG. Efficiency and safety of immune checkpoint inhibitors in cancer patients with chronic liver disease: A systematic review[J]. Journal of Clinical Hepatology, 2022, 38(11): 2457-2461. doi: 10.3969/j.issn.1001-5256.2022.11.005
    [2]FU YiMing, JI Dong, SHAO Qing, LI ZhongBin, WANG ChunYan, CHEN SongHai, CHEN GuoFeng. Association of liver stiffness measurement and serum biochemical parameters with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2020, 36(11): 2473-2477. doi: 10.3969/j.issn.1001-5256.2020.11.015
    [3]Chen JiaCheng, Chen XiaoJing, Zhuang ChunYu, Liu FuJin, Luo ShiShi, Chen Liang, Wu JinCai, Zhou KaiLun. A case of splenectopia in the liver[J]. Journal of Clinical Hepatology, 2020, 36(5): 1131-1133. doi: 10.3969/j.issn.1001-5256.2020.05.040
    [4]HAO DaAng, LIU Ye, YAN XueBing. An etiological analysis of liver diseases with negative hepatotropic virus[J]. Journal of Clinical Hepatology, 2020, 36(12): 2735-2739. doi: 10.3969/j.issn.1001-5256.2020.12.019
    [5]He ZhiYing, Wang BingQiong, You Hong. Clinical application of quantitative assessment of liver fibrosis based on pathology and imaging technology[J]. Journal of Clinical Hepatology, 2018, 34(1): 20-23. doi: 10.3969/j.issn.1001-5256.2018.01.003
    [6]Wu Bin, Shen YiYu, Chen XuJian, Zhong Hai, Wang XiaoGuang, Song ZhengWei, Zhong ZhengXiang. Value of endoscopic ultrasonography in diagnosis of pancreatic space-occupying diseases[J]. Journal of Clinical Hepatology, 2018, 34(8): 1723-1727. doi: 10.3969/j.issn.1001-5256.2018.08.026
    [7]Wu DongBo, Chen EnQiang, Bai Lang, Tang Hong. Liver biopsy and related techniques in pathological diagnosis[J]. Journal of Clinical Hepatology, 2018, 34(11): 2295-2299. doi: 10.3969/j.issn.1001-5256.2018.11.006
    [8]Wen HongXu, Xue DiQiang, Du HongWei, Ming YuZhen. Common bile duct wall puncture and biopsy guided by endoscopic ultrasonography in diagnosis of common bile duct malignant tumor:a case report[J]. Journal of Clinical Hepatology, 2017, 33(7): 1346-1348. doi: 10.3969/j.issn.1001-5256.2017.07.031
    [9]Jiang LiNa, Zhao JingMin. Role of histological evaluation of the liver in clinical practice and research on nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2303-2306. doi: 10.3969/j.issn.1001-5256.2017.12.009
    [10]Sun HaiYing, Wang YaJun, Wang Ming, Zhang ShuQin, Lyu ShengJun, Chen Hui. Liver biopsy results of chronic HBV carriers aged above 40 years: an analysis of 442 cases[J]. Journal of Clinical Hepatology, 2017, 33(8): 1479-1482. doi: 10.3969/j.issn.1001-5256.2017.08.013
    [12]Li Peng, Ding HuiGuo. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis[J]. Journal of Clinical Hepatology, 2015, 31(8): 1193-1197. doi: 10.3969/j.issn.1001-5256.2015.08.003
    [13]Yang Rui, Zhang YaPing, Wang XinHong, Zhu Bin, Zhang GuangWen. Analysis of predictors of liver injury stage in chronic HBV infection patients with ALT levels lower than 2 × ULN[J]. Journal of Clinical Hepatology, 2014, 30(9): 895-898. doi: 10.3969/j.issn.1001-5256.2014.09.014
    [14]Cheng XiaoJing, Lu Wei, Hou Wei, Wang ChunYan, Liu YongGang, Wang JinSheng, Meng Chao. Diagnostic value of FibroTest combined with FibroScan for liver fibrosis in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(5): 424-427. doi: 10.3969/j.issn.1001-5256.2014.05.010
    [15]Zhu JuanJuan, Liu Qin, Mu Mao, Chen Jia, Wang NiuNiu, Li JunLi. One case of hepatic amyloidosis[J]. Journal of Clinical Hepatology, 2014, 30(8): 805-806. doi: 10.3969/j.issn.1001-5256.2014.08.028
    [16]Chen Nian, Ke Liu, Jiang ZhongSheng, Wen XiaoFeng, Su MingHua. Relationship between HBV DNA level and pathological changes of liver tissue in HBeAg-negative patients with chronic HBV infection[J]. Journal of Clinical Hepatology, 2013, 29(6): 438-440.
    [17]Wu YuZhuo. Correlation analysis of quantitative HBsAg and liver histological features of HBeAg-negative chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2012, 28(12): 923-925.
    [18]Sha XiuJuan, Xin GuiJie, Jin MeiShan, Chi TouMei, Niu JunQi. Pay much attention to the clinical application of pathological examination of liver biopsy in the diagnosis and treatment of liver disease[J]. Journal of Clinical Hepatology, 2012, 28(3): 223-226.
    [19]Shen MeiRong, Li ZhongPing, Ding XiaoHong, Chu Feng, Hu DeChang. Clinical significance of liver biopsy in diagnosis and treatment of liver disease[J]. Journal of Clinical Hepatology, 2012, 28(7): 545-547.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 31.3 %FULLTEXT: 31.3 %META: 56.6 %META: 56.6 %PDF: 12.1 %PDF: 12.1 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 7.3 %其他: 7.3 %其他: 0.6 %其他: 0.6 %Arlington: 0.2 %Arlington: 0.2 %China: 0.3 %China: 0.3 %North Point: 0.2 %North Point: 0.2 %Tiruchi: 0.2 %Tiruchi: 0.2 %上海: 2.3 %上海: 2.3 %上饶: 0.2 %上饶: 0.2 %伊利诺伊州: 0.2 %伊利诺伊州: 0.2 %佛山: 0.3 %佛山: 0.3 %兰州: 0.2 %兰州: 0.2 %北京: 3.7 %北京: 3.7 %南京: 0.5 %南京: 0.5 %南充: 0.2 %南充: 0.2 %南宁: 0.2 %南宁: 0.2 %南昌: 0.3 %南昌: 0.3 %南通: 0.8 %南通: 0.8 %占碑: 0.6 %占碑: 0.6 %卡纳塔克: 0.5 %卡纳塔克: 0.5 %合肥: 0.2 %合肥: 0.2 %呼伦贝尔: 0.2 %呼伦贝尔: 0.2 %呼和浩特: 0.6 %呼和浩特: 0.6 %咸阳: 0.2 %咸阳: 0.2 %哈尔滨: 0.3 %哈尔滨: 0.3 %大连: 0.2 %大连: 0.2 %天津: 0.8 %天津: 0.8 %太原: 0.8 %太原: 0.8 %孟买: 0.2 %孟买: 0.2 %安康: 0.2 %安康: 0.2 %布加勒斯特: 0.2 %布加勒斯特: 0.2 %常德: 0.3 %常德: 0.3 %广州: 0.8 %广州: 0.8 %廊坊: 0.2 %廊坊: 0.2 %开封: 0.3 %开封: 0.3 %张家口: 4.4 %张家口: 4.4 %徐州: 0.2 %徐州: 0.2 %德州: 0.2 %德州: 0.2 %成都: 1.6 %成都: 1.6 %无锡: 0.2 %无锡: 0.2 %昆明: 0.8 %昆明: 0.8 %杭州: 1.6 %杭州: 1.6 %格兰特县: 0.2 %格兰特县: 0.2 %森尼韦尔: 0.3 %森尼韦尔: 0.3 %武汉: 0.3 %武汉: 0.3 %洛杉矶: 0.2 %洛杉矶: 0.2 %济南: 0.5 %济南: 0.5 %海得拉巴: 0.5 %海得拉巴: 0.5 %深圳: 0.5 %深圳: 0.5 %湘潭: 0.2 %湘潭: 0.2 %漳州: 0.6 %漳州: 0.6 %焦作: 0.3 %焦作: 0.3 %玉溪: 0.2 %玉溪: 0.2 %眉山: 0.2 %眉山: 0.2 %石家庄: 0.6 %石家庄: 0.6 %福州: 0.9 %福州: 0.9 %科泽科德: 0.2 %科泽科德: 0.2 %芒廷维尤: 31.1 %芒廷维尤: 31.1 %芝加哥: 2.8 %芝加哥: 2.8 %苏州: 0.5 %苏州: 0.5 %莫斯科: 0.3 %莫斯科: 0.3 %西双版纳: 0.3 %西双版纳: 0.3 %西宁: 11.4 %西宁: 11.4 %西安: 0.5 %西安: 0.5 %诺沃克: 0.2 %诺沃克: 0.2 %贵阳: 0.6 %贵阳: 0.6 %运城: 1.2 %运城: 1.2 %遵义: 0.2 %遵义: 0.2 %邯郸: 0.2 %邯郸: 0.2 %郑州: 1.1 %郑州: 1.1 %重庆: 1.4 %重庆: 1.4 %金华: 0.2 %金华: 0.2 %银川: 0.2 %银川: 0.2 %长春: 8.7 %长春: 8.7 %长沙: 0.9 %长沙: 0.9 %阿姆斯特丹: 0.2 %阿姆斯特丹: 0.2 %青岛: 0.5 %青岛: 0.5 %其他其他ArlingtonChinaNorth PointTiruchi上海上饶伊利诺伊州佛山兰州北京南京南充南宁南昌南通占碑卡纳塔克合肥呼伦贝尔呼和浩特咸阳哈尔滨大连天津太原孟买安康布加勒斯特常德广州廊坊开封张家口徐州德州成都无锡昆明杭州格兰特县森尼韦尔武汉洛杉矶济南海得拉巴深圳湘潭漳州焦作玉溪眉山石家庄福州科泽科德芒廷维尤芝加哥苏州莫斯科西双版纳西宁西安诺沃克贵阳运城遵义邯郸郑州重庆金华银川长春长沙阿姆斯特丹青岛

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (364) PDF downloads(78) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2389]YesterdayPV[5285]TodayIP[2049]TodayPV[4512]Online[31]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return